艾德生物收盘上涨5.50%，滚动市盈率31.81倍，总市值89.43亿元

Group 1 - The core viewpoint of the news is that Aide Biological has shown a significant increase in stock price and performance metrics, despite being ranked lower in the industry PE ratio [1] - As of July 8, Aide Biological's closing stock price was 22.84 yuan, up 5.50%, with a rolling PE ratio of 31.81, marking a new low in 64 days and a total market capitalization of 8.943 billion yuan [1] - The company is ranked 68th in the medical device industry, which has an average PE ratio of 51.58 and a median of 37.46 [1] Group 2 - As of the first quarter of 2025, 27 institutions held shares in Aide Biological, including 20 funds, 6 other entities, and 1 social security fund, with a total holding of 197.0434 million shares valued at 4.414 billion yuan [1] - Aide Biological specializes in tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - The latest performance report for the first quarter of 2025 shows that the company achieved an operating income of 272 million yuan, a year-on-year increase of 16.63%, and a net profit of 90.4718 million yuan, a year-on-year increase of 40.92%, with a sales gross margin of 83.48% [1]